by Valeo Pharma | Sep 22, 2021 | News Release
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter. Record gross margin of $2.2 million, up 1602% over Q3 2020 and 204% over prior quarter. Record 9 months revenues at $10.2 million, up 94%. Private and public reimbursement...
by Valeo Pharma | Jun 29, 2021 | News Release
Q2-21 record revenues of $2.65 million, up 27% vs Q2-20 and up 42% over prior quarter Q3-21 revenues expected to increase by more than 50% over Q2-21 Redesca launched in late Q2-21 Enerzair® Breezhaler® and Atectura® Breezhaler® commercial shipments commenced...
by Valeo Pharma | Jun 29, 2021 | News Release
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES MONTREAL, QC – June 29, 2021 – Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, is pleased to announce the closing...
by Valeo Pharma | Jun 23, 2021 | News Release
MONTREAL, QUEBEC , June 23, 2021 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2021 on...
by Valeo Pharma | Jun 23, 2021 | News Release
MONTREAL, QUEBEC , June 23, 2021 – Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF,FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announcedtoday that it will report its financial results and highlights for the second quarter ended April30, 2021 on...
